NVS
Biotech

AHA: Novartis’ Lp(a) drug shows zero benefit

Novartis reported a total absence of efficacy that could intensify questions about upcoming readouts from Amgen and Eli Lilly.
Nick Paul Taylor Nov 7, 2026 9:50am
akt health

Why scientific progress depends on knowing when to look again

Brought to you by Ipsen
drawing of magnifying glass on a brain

J&J-backed Delix secures $100M for non-hallucinatory psychedelic

Nov 9, 2026 10:30am
Podcast
Top Line Podcast - ZS

Use Kidney Genetics to Strengthen Clinical Trial Design

Brought to you by Natera
Boehringer Ingelheim Boehringer

AHA: Boehringer plans 2027 survodutide submission after CV win

Nov 9, 2026 9:45am
Advanced Analytics Help Reduce Control Animal Use While Preserving Scientific Rigor

How Virtual Control Groups Are Shaping Safety Studies

Brought to you by Charles River Laboratories
More News

Spruce spins out preclinical endocrinology program into Adrenyx

Nov 9, 2026 9:30am

Zura scraps hidradenitis suppurativa program after phase 2 miss

Nov 9, 2026 9:21am

Sanofi-backed Windward breezes toward $204M IPO

Nov 9, 2026 9:05am

Kyorin's $140M deal for Japan rights to Edesa respiratory drug

Nov 9, 2026 7:29am